[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342349-105":59,"doc-detail-342349-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","a-human-like-glutaminase-free-asparaginase-is-highly-efficacious-in-asnslow-leukemia-and-solid-cancer-mouse-xenograft-models","A human-like glutaminase-free asparaginase is highly efficacious in ASNSlow leukemia and solid cancer mouse xenograft models","","L-asparaginase (L-ASNase) is essential for pediatric acute lymphoblastic leukemia (ALL) treatment, yet its clinical use is constrained by immunogenic side effects and the co-activity of L-glutaminase (L-GLNase) in FDA-approved bacterial L-ASNases, which can force therapy discontinuation and worsen outcomes. Toxicities are particularly problematic in adult cancer patients. To address this, EBD-200 was developed as a humanized guinea pig L-ASNase with low Km and no L-GLNase activity, eliminating glutamine-associated toxicity.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-human-like-glutaminase-free-asparaginase-is-highly-efficacious-in-asnslow-leukemia-and-solid-cancer-mouse-xenograft-models/342349/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-human-like-glutaminase-free-asparaginase-is-highly-efficacious-in-asnslow-leukemia-and-solid-cancer-mouse-xenograft-models/342349.png","ImageObject",300,407,{"name":92,"@type":93},"Ophelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-11","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is L-asparaginase important for treating acute lymphoblastic leukemia (ALL)?","Question",{"text":112,"@type":113},"L-asparaginase is a key enzyme drug in ALL therapy and works by depleting extracellular asparagine, which is critical for cells that lack ASNS expression.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What limitations affect the use of FDA-approved bacterial L-asparaginases?",{"text":117,"@type":113},"Their use is hindered by immunogenic side effects and L-glutaminase (L-GLNase) co-activity, leading to toxicity, possible treatment discontinuation, and poor outcomes.",{"name":119,"@type":110,"acceptedAnswer":120},"What is EBD-200 and how does it address the glutamine-related toxicity problem?",{"text":121,"@type":113},"EBD-200 is a humanized guinea pig L-asparaginase engineered to have low Km and no L-GLNase activity, thereby eliminating glutamine-related toxicity while maintaining anti-cancer activity.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342349,1790198854,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","VA Author Manuscr ipt VA Author Manuscr ipt VA Author Manuscript  \n\n| | U.S. Department of Veterans Affairs\u003Cbr>Public Access Author manuscript\u003Cbr>Cancer Lett. Author manuscript; available in PMC 2026 June 19. |\n| --- | --- |\n\nPublished in final edited form as:  \nCancer Lett. 2025 February 28; 611: 217404. doi:10.1016/j.canlet.2024.217404 .  \nA human-like glutaminase-free asparaginase is highly efficacious in ASNSlow leukemia and solid cancer mouse xenograft models  \nMaaike Van Trimponta,b,1 , Amanda M. Schalkc,d,1 , Kenneth Hofkensa,b, Evelien Peetersa,b, Sara T’Sasa,b, Katrien Vandemeulebroeckea,e,f, Ying Suc, Ashley De Loerac, Alyssa Garciac, Hui Cheng, Tim Lammensa,e,f, Pieter Van Vlierberghea,h, Steven Goossensa,b,1 , Arnon Laviec,d,i,1,*  \naCancer Research Institute Ghent (CRIG), Ghent, Belgium  \nb Department of Diagnostic Sciences, Ghent University, Ghent, Belgium  \nc Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, USA  \nd Enzyme By Design Inc. , Chicago, USA  \ne Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium  \nfDepartment of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium  \ng Director, Mass Spectrometry Core, Research Resources Center, University of Illinois at Chicago, Chicago, USA  \nh Department of Biomolecular Medicine, Ghent University, Ghent, Belgium  \ni Research Biologist, Biological Science Research and Development, Department of Veterans Affairs Medical Center, Chicago, IL, USA  \nThis is an open access article under the CC BY license ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)).  \n*Corresponding author. Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, USA. Lav1 Thsicuth.edor c(Aon. tLriavbuiete)d. equally to this work.  \nDeclaration of competing interest  \nThe authors declare the following financial interests/personal relationships which may be considered as potential competing interests: AMS and AL are cofounders and equity holders of Enzyme by Design Inc, a company developing novel asparaginases. All other authors declare no conflicts of interest.  \nCRediT authorship contribution statement  \nMaaike Van Trimpont: Writing – review & editing, Writing – original draft, Visualization, Validation, Methodology, Investigation, Data curation, Conceptualization. Amanda M. Schalk: Writing – review & editing, Writing – original draft, Visualization, Validation, Methodology, Investigation, Funding acquisition, Conceptualization. Kenneth Hofkens: Investigation. Evelien Peeters: Investigation. Sara T’Sas: Investigation. Katrien Vandemeulebroecke: Investigation. Ying Su: Investigation. Ashley De Loera: Investigation. Alyssa Garcia: Investigation. Hui Chen: Investigation. Tim Lammens: Writing – review & editing, Writing – original draft, Supervision, Methodology, Funding acquisition, Conceptualization. Pieter Van Vlierberghe: Supervision, Methodology, Funding acquisition, Conceptualization. Steven Goossens: Writing – review & editing, Writing – original draft, Supervision, Methodology, Funding acquisition, Conceptualization. Arnon Lavie: Writing – review & editing, Writing – original draft, Supervision, Methodology, Investigation, Funding acquisition, Conceptualization.  \nDeclaration of generative AI and AI-assisted technologies in the writing process  \nDuring the preparation of this work, the author(s) used Chat GPT-3.5 in order to rephrase certain sentences. After using this tool or service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.  \nVA Author Manuscr ipt VA Author Manuscr ipt VA Author Manuscript  \nVan Trimpont et al. Page 2  \nAbstract  \nL-asparaginase (L-ASNase) is crucial in treating pediatric acute lymphoblastic leukemia (ALL), but its use is hampered by side effects from the immunogenicity and L-glutaminase (L-","cbCaipziDpdk2cWA","https://ap.wps.com/l/cbCaipziDpdk2cWA","pdf",940654,23,"English","# Abstract\n# Keywords\n# 1. Introduction","[{\"question\":\"Why is L-asparaginase important for treating acute lymphoblastic leukemia (ALL)?\",\"answer\":\"L-asparaginase is a key enzyme drug in ALL therapy and works by depleting extracellular asparagine, which is critical for cells that lack ASNS expression.\"},{\"question\":\"What limitations affect the use of FDA-approved bacterial L-asparaginases?\",\"answer\":\"Their use is hindered by immunogenic side effects and L-glutaminase (L-GLNase) co-activity, leading to toxicity, possible treatment discontinuation, and poor outcomes.\"},{\"question\":\"What is EBD-200 and how does it address the glutamine-related toxicity problem?\",\"answer\":\"EBD-200 is a humanized guinea pig L-asparaginase engineered to have low Km and no L-GLNase activity, thereby eliminating glutamine-related toxicity while maintaining anti-cancer activity.\"}]","A human-like glutaminase-free asparaginase is highly efficacious in ASNSlow leukemia and solid cancer mouse xenograft models | PDF",1790046255,58,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/446b36a077bf4eb6110a3ec83d7f8e2f.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aa1e00223e06ab275a162325256a21b3.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cd7f79a5a8bf9ce865d4695b1a98308e.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7721731ef58ce2be354579a8635c7cfc.webp",980,1268]